Pfizer (PFE) Other financing activities (2009 - 2026)

Pfizer (PFE) has 18 years of Other financing activities data on file, last reported at -$284.0 million in Q1 2026.

• Other financing activities for Q1 2026 came in at -$284.0 million, up 20.22% year-over-year; the trailing twelve-month figure through Mar 2026 was -$386.0 million (up 69.37% YoY), and the FY2025 annual result was -$458.0 million, up 2.35% from the prior year.
• Other financing activities eased to -$284.0 million in Q1 2026 per PFE's latest filing, from -$43.0 million in the prior quarter.
• Over five years, Other financing activities peaked at $154.0 million in Q3 2022 and troughed at -$501.0 million in Q2 2022.
• A 5-year average of -$197.7 million and a median of -$140.0 million in 2023 frame the typical range for Other financing activities.
• The sharpest annual moves came in 2024 and 2025: Other financing activities tumbled 1129.73% in 2024, then surged 91.65% in 2025.
• A 5-year view of Other financing activities shows it stood at -$342.0 million in 2022, then surged by 94.74% to -$18.0 million in 2023, then tumbled by 2427.78% to -$455.0 million in 2024, then jumped by 90.55% to -$43.0 million in 2025, then tumbled by 560.47% to -$284.0 million in 2026.
• Business Quant data shows PFE's Other financing activities at -$284.0 million in Q1 2026, -$43.0 million in Q4 2025, and -$38.0 million in Q3 2025.